June 1, 2018
Reporting results from a first-in-human phase I clinical trial, researchers at University of California San Diego School of Medicine have found that treatment with cirmtuzumab, an experimental monoclonal antibody-based drug, measurably inhibited the “stemness” of chronic lymphocytic leukemia cancer (CLL) cells — their ability to self-renew and resist terminal differentiation…
December 5, 2013
…of Medicine, has found that brain cancer cells resist therapy by dialing down the gene mutation targeted by drugs, then re-amplify that growth-promoting mutation after therapy has stopped.
March 8, 2017
…eligible for a novel technique that allows surgeons to target the abnormal area of brain with laser technology. The MRI-guided laser ablation treatment is a new first-line therapy for patients diagnosed with epilepsy.
February 23, 2016
…different types of blood cancer that often defy existing therapies.
September 5, 2017
…of Medicine in St. Louis report the virus specifically targets and kills brain cancer stem cells.
November 17, 2014
An antibody therapy already in clinical trials to treat chronic lymphocytic leukemia (CLL) may also prove effective against ovarian cancer – and likely other cancers as well, report researchers at the University of California, San Diego School of Medicine.
November 1, 2016
Researchers at University of California San Diego School of Medicine and Mayo Clinic provide the first evidence that the Hedgehog signaling pathway is central to the formation of gastrointestinal stromal tumors (GIST), which are frequently driven by the KIT oncogene.
August 27, 2020
UC San Diego Health is now offering a new minimally invasive approach to provide relief for patients suffering from chronic low back pain (CLBP). The new treatment is called “Intracept,” an outpatient procedure that targets nerves located in the vertebrae or bones of the spine.
August 10, 2017
…track RNA in live cells in a method called RNA-targeting Cas9. In a study published August 10 in Cell, the team took RCas9 a step further: they corrected molecular mistakes that lead to microsatellite repeat expansion diseases, which include a type of ALS and Huntington’s disease.
September 1, 2011
In a paper published today in the journal Scientific Reports, a pair of researchers at the University of California, San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences report that inhibiting the ability of immune cells to use fatty acids as fuel measurably slows disease progression in a mouse model…
